Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

TransCDR: a deep learning model for enhancing the generalizability of drug activity prediction through transfer learning and multimodal data fusion

TransCDR: a deep learning model for enhancing the generalizability of cancer drug response prediction through transfer learning and multimodal data fusion for drug representation

DeepCDR: a Hybrid Graph Convolutional Network for Predicting Cancer Drug Response

RedCDR: Dual Relation Distillation for Cancer Drug Response Prediction

DRN-CDR: A cancer drug response prediction model using multi-omics and drug features

MMCL-CDR: enhancing cancer drug response prediction with multi-omics and morphology images contrastive representation learning

TCR: A Transformer Based Deep Network for Predicting Cancer Drugs Response

A subcomponent-guided deep learning method for interpretable cancer drug response prediction

A Multi-Modal Genomic Knowledge Distillation Framework for Drug Response Prediction

MCMVDRP: a multi-channel multi-view deep learning framework for cancer drug response prediction

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

DeepTTA: a transformer-based model for predicting cancer drug response

Ensemble Transfer Learning for the Prediction of Anti-Cancer Drug Response

Drug Sensitivity Prediction Based on Multi-stage Multi-modal Drug Representation Learning

GraphCDR: a graph neural network method with contrastive learning for cancer drug response prediction

TransCell: In silico Characterization of Genomic Landscape and Cellular Responses by Deep Transfer Learning

MMDRP: drug response prediction and biomarker discovery using multi-modal deep learning

Dual-Layer Strengthened Collaborative Topic Regression Modeling for Predicting Drug Sensitivity

Transfer learning of condition-specific perturbation in gene interactions improves drug response prediction

A systematic assessment of deep learning methods for drug response prediction: from in vitro to clinical applications

DeepDRA: Drug repurposing using multi-omics data integration with autoencoders